Overview

Erlotinib and Temsirolimus for Solid Tumors

Status:
Completed

Trial end date:
2014-09-01

Target enrollment:

Participant gender:

Summary

Define the maximum tolerated dose and dose limiting side-effects of temsirolimus in combination wtih erlotinib in patients with resistant solid tumors

Phase:

Phase 1

Details

Lead Sponsor:

Washington University School of Medicine

Collaborator:

Pfizer

Treatments:

Erlotinib Hydrochloride
Everolimus
Sirolimus